Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016
- PMID: 32148129
- PMCID: PMC7398637
- DOI: 10.1161/HYPERTENSIONAHA.119.14360
Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016
Abstract
Blood pressure (BP) control rates among US adults taking antihypertensive medication have not increased over the past decade. Many adults require 2 or more classes of antihypertensive medication to achieve guideline-recommended BP goals, but the proportion of US adults taking antihypertensive medication monotherapy, versus combination therapy, has not been quantified using contemporary data. We analyzed data from 2005 to 2008, 2009 to 2012, and 2013 to 2016 National Health and Nutrition Examination Surveys to determine trends in monotherapy and combinations of antihypertensive medication classes among US adults age ≥20 years with hypertension taking antihypertensive medication (n=7837). The proportion of US adults taking antihypertensive medication with uncontrolled BP (ie, systolic BP ≥140 or diastolic BP ≥90 mm Hg) was 32.3%, 30.2%, and 31.0% in 2005 to 2008, 2009 to 2012, and 2013 to 2016, respectively (Ptrend=0.37). Between 2005 to 2008 and 2013 to 2016, there was no evidence of changes in the proportions of US adults taking antihypertensive monotherapy (39.5%-40.4%, Ptrend=0.67), dual-therapy (37.9%-38.3%, Ptrend=0.75), triple-therapy (17.6%-16.5%, Ptrend=0.36), or quadruple-therapy (4.4%-4.3%, Ptrend=0.93). Between 2005 to 2008 and 2013 to 2016, there was no evidence of changes in the proportions of US adults with uncontrolled BP taking antihypertensive monotherapy (39.3%-40.6%, Ptrend=0.78). A high proportion of US adults with hypertension, including those with uncontrolled BP, are taking one antihypertensive medication class. Increasing the use of dual- and triple-therapy antihypertensive medication regimens may restore the upward trend in BP control rates among US adults.
Keywords: antihypertensive agents; blood pressure; cardiovascular agents; cardiovascular diseases; hypertension.
Conflict of interest statement
Conflicts of Interest/Disclosures:
Dr. Muntner is a consultant for Kaiser Permanente Southern California on a project funded by Vital Strategies, and he receives grant support through his institution from Amgen Inc. Dr. Bress receives support to his institution from Amarin Corporation, Novartis, and Amgen unrelated to the current manuscript.
Comment in
-
Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance.Hypertension. 2020 Apr;75(4):943-944. doi: 10.1161/HYPERTENSIONAHA.119.14528. Epub 2020 Mar 9. Hypertension. 2020. PMID: 32148130 No abstract available.
References
-
- Egan BM, Zhao Y, Axon RN. US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008. JAMA. 2010;303(20):2043–2050. - PubMed
-
- Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence and Control Among Adults in the United States, 2015-2016. Hyattsville, MD; 2017. https://www.cdc.gov/nchs/data/databriefs/db289.pdf. Accessed June 5, 2018. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
